Home Data Calendar Blog

GOSS

Tables

		2024-09-30	2024-06-30
Common Stock Value		0.02	0.02
dei: Entity Common Stock Shares Outstanding		NA	NA
Weighted Average Number Of Diluted Shares Outstanding		226.35	238.54
Weighted Average Number Of Shares Outstanding Basic		226.35	226.22
Earnings Per Share Basic		-0.14	0.22
Earnings Per Share Diluted		-0.14	0.22

		2024-09-30	2024-06-30
Revenue From Contract With Customer Excluding Assessed Tax		9.48	95.84
Revenues		9.48	95.84
Operating Expenses		43.40	43.76
Research And Development Expense Excluding Acquired In Process Cost		34.90	35.09
General And Administrative Expense		8.50	8.67
Operating Income Loss		-33.92	52.09
Interest Paid Net		0.00	5.19
Allocated Share Based Compensation Expense		4.84	5.00
Income Tax Expense Benefit		-1.13	4.43
Profit Loss		-30.80	49.23
Net Income Loss		-30.80	49.23
Comprehensive Income Net Of Tax		-32.52	49.34

		2024-09-30	2024-06-30
Assets		350.88	373.45
Liabilities		296.74	291.92
Liabilities And Stockholders Equity		350.88	373.45
Stockholders Equity		54.14	81.53

		2024-09-30	2024-06-30
Assets Current		344.27	370.90
Cash And Cash Equivalents At Carrying Value		28.46	86.88
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents		28.46	86.88
Marketable Securities Current		298.57	267.61
Accounts Receivable Net Current		6.59	3.63
Prepaid Expense And Other Assets Current		10.65	12.79
Available For Sale Securities Debt Securities		298.57	267.61

		2024-09-30	2024-06-30
Property Plant And Equipment Gross		4.03	6.50
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment		3.73	5.67
Property Plant And Equipment Net		0.30	0.82
Other Assets Noncurrent		0.28	0.06
Available For Sale Debt Securities Amortized Cost Basis		298.14	267.73

		2024-09-30	2024-06-30
Liabilities Current		51.09	45.19
Accounts Payable Current		3.06	1.00
Other Accrued Liabilities Current		0.44	0.54
Accrued Income Taxes Current		1.10	4.43
Accrued Liabilities Current		17.42	16.31
Contract With Customer Liability Current		20.33	17.01

		2024-09-30	2024-06-30
Operating Lease Liability Noncurrent		4.59	NA

		2024-09-30	2024-06-30
Stockholders Equity		54.14	81.53
Common Stock Value		0.02	0.02
Additional Paid In Capital Common Stock		1291.88	1286.76
Retained Earnings Accumulated Deficit		-1235.54	-1204.74
Accumulated Other Comprehensive Income Loss Net Of Tax		-2.23	-0.52
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value		4.84	5.00

		2024-09-30	2024-06-30
Net Cash Provided By Used In Operating Activities		-32.03	116.35
Net Cash Provided By Used In Investing Activities		-26.75	-59.11
Net Cash Provided By Used In Financing Activities		0.28	-9.21

		2024-09-30	2024-06-30
Net Cash Provided By Used In Operating Activities		-32.03	116.35
Net Income Loss		-30.80	49.23
Profit Loss		-30.80	49.23
Depreciation Depletion And Amortization		0.20	0.30
Increase Decrease In Accounts Payable		-0.29	-1.52
Share Based Compensation		4.84	5.00

		2024-09-30	2024-06-30
Net Cash Provided By Used In Investing Activities		-26.75	-59.11

		2024-09-30	2024-06-30
Net Cash Provided By Used In Financing Activities		0.28	-9.21

		2024-09-30	2024-06-30
Revenues		9.48	95.84
Chiesi Farmaceutici S.p. A And Chiesi U S A Inc.		9.48	95.84
Chiesi Farmaceutici S.p. A And Chiesi U S A Inc., Research And Development Services Performance Obligations Satisfied		9.50	7.10
Chiesi Farmaceutici S.p. A And Chiesi U S A Inc., Effects Of Exchange Rate, Transferred Over Time		-0.01	0.02
Chiesi Farmaceutici S.p. A And Chiesi U S A Inc., P A H Research And Development Services Expenses Subject To Reimbursement, Transferred Over Time		3.52	3.30
Chiesi Farmaceutici S.p. A And Chiesi U S A Inc., P A H Research And Development Services Performance Obligations Satisfied, Transferred Over Time		4.74	3.40
Chiesi Farmaceutici S.p. A And Chiesi U S A Inc., P H I L D Research And Development Services Expenses Subject To Reimbursement, Transferred Over Time		1.09	0.33
Chiesi Farmaceutici S.p. A And Chiesi U S A Inc., P H I L D Research And Development Services Performance Obligations Satisfied, Transferred Over Time		0.16	0.06
Chiesi Farmaceutici S.p. A And Chiesi U S A Inc., R O W License, Transferred At Point In Time		0.00	12.05
Chiesi Farmaceutici S.p. A And Chiesi U S A Inc., U S License, Transferred At Point In Time		0.00	76.69
Revenue From Contracts With Collaborators		9.48	7.09
License And Service		0.00	88.75
Revenue From Contract With Customer Excluding Assessed Tax		9.48	95.84
Chiesi Farmaceutici S.p. A And Chiesi U S A Inc.		9.48	95.84
Chiesi Farmaceutici S.p. A And Chiesi U S A Inc., Research And Development Services Performance Obligations Satisfied		9.50	7.10
Chiesi Farmaceutici S.p. A And Chiesi U S A Inc., Effects Of Exchange Rate, Transferred Over Time		-0.01	0.02
Chiesi Farmaceutici S.p. A And Chiesi U S A Inc., P A H Research And Development Services Expenses Subject To Reimbursement, Transferred Over Time		3.52	3.30
Chiesi Farmaceutici S.p. A And Chiesi U S A Inc., P A H Research And Development Services Performance Obligations Satisfied, Transferred Over Time		4.74	3.40
Chiesi Farmaceutici S.p. A And Chiesi U S A Inc., P H I L D Research And Development Services Expenses Subject To Reimbursement, Transferred Over Time		1.09	0.33
Chiesi Farmaceutici S.p. A And Chiesi U S A Inc., P H I L D Research And Development Services Performance Obligations Satisfied, Transferred Over Time		0.16	0.06
Chiesi Farmaceutici S.p. A And Chiesi U S A Inc., R O W License, Transferred At Point In Time		0.00	12.05
Chiesi Farmaceutici S.p. A And Chiesi U S A Inc., U S License, Transferred At Point In Time		0.00	76.69
Revenue From Contracts With Collaborators		9.48	7.09
License And Service		0.00	88.75

Plots across concepts

Line plots across dimensions of each concept